CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide.
Nat Commun
; 11(1): 798, 2020 02 07.
Article
em En
| MEDLINE
| ID: mdl-32034142
ABSTRACT
Multiple myeloma (MM) is a plasma cell malignancy and most patients eventually succumb to the disease. Chimeric antigen receptor (CAR) T cells targeting B-Cell Maturation Antigen (BCMA) on MM cells have shown high-response rates, but limited durability. CD229/LY9 is a cell surface receptor present on B and T lymphocytes that is universally and strongly expressed on MM plasma cells. Here, we develop CD229 CAR T cells that are highly active in vitro and in vivo against MM plasma cells, memory B cells, and MM-propagating cells. We do not observe fratricide during CD229 CAR T cell production, as CD229 is downregulated in T cells during activation. In addition, while CD229 CAR T cells target normal CD229high T cells, they spare functional CD229neg/low T cells. These findings indicate that CD229 CAR T cells may be an effective treatment for patients with MM.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Receptores de Antígenos de Linfócitos T
/
Imunoterapia Adotiva
/
Família de Moléculas de Sinalização da Ativação Linfocitária
/
Mieloma Múltiplo
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article